期刊文献+

HER2基因转染MCF-7细胞及生物学特性观察 被引量:1

The Biological Characteristics of MCF-7 Cell Line Transfected with HER2 Gene
下载PDF
导出
摘要 目的:建立共表达HER2(HumanEpidermalGrowthFactorReceptor2)基因和ER(EstrogenReceptor)基因的细胞模型,并观察转染细胞的生物学活性。方法:构建真核表达载体pcDNA3.1-HER2,利用脂质体介导将其转染ER阳性的乳腺癌MCF-7细胞,经G418筛选阳性克隆。用RT-PCR、Westernblot及免疫细胞化学等方法检测HER2基因在MCF-7细胞中的稳定表达情况,并通过MTT法和肿瘤细胞侵袭实验,观察转染细胞的生物学活性。结果:在mRNA和蛋白水平证实,转染细胞内有HER2基因的高表达,转染后细胞的增殖能力和侵袭能力明显增强。结论:构建含HER2基因的重组载体,导入乳腺癌MCF-7细胞后,获得生物学活性稳定的HER2基因和ER基因高表达的细胞模型,为进一步研究奠定了基础。 Objective: To establish a cell line with stable co-expression of HER2 and ER and to study its biological, activity. Methods: Recombinant eukaryotic expression vector plasmid pcDNA 3.1-HER2 was constructed. It was transfected into ER expressing MCF-7 cells with lipofectamine. The positive cell clones had been obtained after selected by G418. The MCF-7 cell transfected with HER2-cDNA was determined by RT-PCR, immunocytochemistry and Western blot. The activation of transfected MCF-7 cells was observed by MTT assay and cell invasion assay. Results: The strong expression of HER2 in transfected MCF-7 cells was confirmed at mRNA and protein levels. The capability of proliferation and invasion was obviously enhanced. Conclusion: The recombinant expression vector containing HER2 is successfully constructed. After introduction of the vector into MCF-7 cells, the MCF-7 cell line co-expressing HER2 and ER has also been obtained, which would be helpful for further study on HER2 gene.
出处 《中国肿瘤临床》 CAS CSCD 北大核心 2005年第21期1220-1223,共4页 Chinese Journal of Clinical Oncology
基金 广东省自然科学基金资助(编号:037050)
关键词 HER2基因 MCF-7细胞 转染 基因表达 HER2 gene MCF-7 cells transfection gene expression
  • 相关文献

参考文献12

  • 1Hynes NE,Stern DF.The biology of erbB-2/neu/Her-2 and its role in cancer[J].Biochim Biophys Acta Rev Cancer,1994.1198(2-3):165-184.
  • 2Winstanley J,Cooke T,Murray GD,et al.The ling term prognostic significance of c-erbB-2 in primary breast cancer[J].Br J Cancer,1991.63(3):447-450.
  • 3Miles DW,Harris WH.Gillett CE,et al.Effect of c-erb2 and estrogen receptor status on survival of women with primary breast cancer treated with adjuvant cyclohosphamide/methotrexate/flulorouracil[J].Int J Cancer.1999.84(4):354-359.
  • 4Kurokawa H,Arteaga CL.ErbB(HER)receptors can abrogate antiestrogen action in human breast cancer by multiple signaling mechanisms[J].Clin Cancer Res,2003.9(1 Pt2):511S-515S.
  • 5Szollosi J,Balazs M,Feuerstein BG,et al.ERBB-2(HER2/neu)gene copy number,p185HER-2 overexpression,and intratumor heterogeneity in human breast cancer[J].Cancer Res,1995.55(22):5400-5407.
  • 6Graus-Pfma D, Bccrli RR. Daly JM. et al. ErbB-2, the preferred heterodimerization partner of all ErbB receptors is a mediator of lateral signaling [J].EMBO J.1997.16(7):1647-1655.
  • 7Horiguchi J.Koibuchi Y,Iijima K,et al.Immunohistochemical double staining with estrogen receptor and HER2 on primary breast cancer[J].Int J Mol Med,2003,12(6):855-859.
  • 8McCann AH,Dervan PA,O'Regan M.et al.Prognostic significance of c-erbB-2 and estrogen receptor status in human breast cancer[J].Cancer Res,1991.51(12):3296-3303.
  • 9Read LD,Keith D Jr.Slamon DJ,et al.Hormonal modulation of HER-2/neu protooncogene messnger ribonucleic acid and p185 protein expression in human breast cancer clee lines[J].Camcer Res.1990.50(13):3947-3951.
  • 10Lupu R,Lippman ME.The role of erbB2 signal transduction pathways in human breast cancer[J].Breast Cancer Res Treat,.1993.27(1-2):83-93.

同被引文献9

  • 1石毅然,曲建军,李湘洲,马世庆,王峰,王会东,张永庆,王昌亮.MUC1与HER2基因在乳腺癌中的表达及其与临床病理学指标的相关性研究[J].中国肿瘤临床,2007,34(11):621-624. 被引量:6
  • 2Slamon DJ,Godolphin W,Jones LA,et al.Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer[J].Science,1989,244(4 905):707-712.
  • 3Disis ML,Schiffman K.Cancer vaccines targeting the HER2/neu oncogenic protein[J].Seminol Onc,2001,28(18):12-20.
  • 4Menard S,Casalini P,Campiglio M,et al.Role of C-erbB-2 in tumor progression and therapy[J].Cell Mol Life Sci,2004,61(23):2 965-2 978.
  • 5Hayes DF,Yamauchi H,Broadwater G,et al.Circulating HER-2/erbB-2/c-neu (HER-2) extracellular domain as a prognostic factor in patients with metastatic breast cancer:Cancer and Leukemia Group B Study 8662[J].Clin Cancer Res,2001,7(9):2 703-2 711.
  • 6Prati R,Apple SK,He J,et al.Histopathologic characteristics predicting HER-2/neu amplification in breast cancer[J].Breast J,2005,11(6):433-439.
  • 7Shimada M,Imura J,Kozaki T,et al.Detection of Her2/neu,c-MYC and ZNF217 gene amplification during breast cancer progression using fluorescence in situ hybridization[J].Oncol Rep,2005,13(4):633-641.
  • 8Press MF,Sauter G,Bernstein L,et al.Diagnostic evaluation of HER-2 as a molecular target:an assessment of accuracy and reproducibility of laboratory testing in large,prospective,randomized clinical trials[J].Clin Cancer Res,2005,11(18):6 598-6 607.
  • 9Jahanzeb M.Adjuvant trastuzumab therapy for HER2-positive breast cancer[J].Clin Breast Cancer,2008,8(4):324-333.

引证文献1

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部